Matches in Nanopublications for { ?s ?p "[Cyclin D1 overexpression was seen in hyperplasia and metaplasia (6%), mild dysplasia (17%), moderate dysplasia (46%), and CIS (38%) in patients with cancer but was lost in 5% of the patients during the process of invasion; it was also observed in patients with no cancer progression (14%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 4 of
4
with 100 items per page.
- NP521069.RAZK9azt-_C6yqp89nDn7UhA-AP1GnOK9u-zwo4pO0Gag130_assertion description "[Cyclin D1 overexpression was seen in hyperplasia and metaplasia (6%), mild dysplasia (17%), moderate dysplasia (46%), and CIS (38%) in patients with cancer but was lost in 5% of the patients during the process of invasion; it was also observed in patients with no cancer progression (14%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP521069.RAZK9azt-_C6yqp89nDn7UhA-AP1GnOK9u-zwo4pO0Gag130_provenance.
- assertion description "[Cyclin D1 overexpression was seen in hyperplasia and metaplasia (6%), mild dysplasia (17%), moderate dysplasia (46%), and CIS (38%) in patients with cancer but was lost in 5% of the patients during the process of invasion; it was also observed in patients with no cancer progression (14%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP246450.RAQpm27e2HsBzjiHO6GhmeSbefynWUlayLjJQer7I3_lQ130_assertion description "[Cyclin D1 overexpression was seen in hyperplasia and metaplasia (6%), mild dysplasia (17%), moderate dysplasia (46%), and CIS (38%) in patients with cancer but was lost in 5% of the patients during the process of invasion; it was also observed in patients with no cancer progression (14%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP246450.RAQpm27e2HsBzjiHO6GhmeSbefynWUlayLjJQer7I3_lQ130_provenance.
- NP698111.RAO_F_Ao7dja19s4cnEEEjmOy6LRb7xbnrzPilAHRBnDY130_assertion description "[Cyclin D1 overexpression was seen in hyperplasia and metaplasia (6%), mild dysplasia (17%), moderate dysplasia (46%), and CIS (38%) in patients with cancer but was lost in 5% of the patients during the process of invasion; it was also observed in patients with no cancer progression (14%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP698111.RAO_F_Ao7dja19s4cnEEEjmOy6LRb7xbnrzPilAHRBnDY130_provenance.